Samsung Biologics' acquisition of PolyPeptide represents a strategic move to expand its contract development and manufacturing organisation (CDMO) capabilities…
Samsung Biologics was founded in 2011 by Samsung Group, marking its ambitious entry into the biopharmaceutical contract development and manufacturing organisation (CDMO)…
During this period, PolyPeptide Group significantly expanded its global manufacturing footprint, consolidating its position as a leading CDMO for synthetic peptides and…
The onset of the COVID-19 pandemic in 2020 triggered an unprecedented surge in demand for CDMO services, particularly for vaccine and therapeutic manufacturing. This per…
In 2021, Samsung Biologics continued its aggressive expansion strategy, announcing plans for its fourth manufacturing plant (Plant 4) in Incheon, South Korea, further so…
In 2022, Samsung Biologics formally announced its expanded multi-modality CDMO strategy, signaling a shift beyond its core biologics manufacturing into new drug modaliti…
Following its multi-modality strategy announcement, Samsung Biologics began actively scouting for acquisition targets in the peptide and oligonucleotide CDMO space in ea…
In the first quarter of 2024, reports from financial news outlets began to surface, indicating that Samsung Biologics was in advanced discussions to acquire PolyPeptide…
On April 15, 2024, Samsung Biologics officially announced its all-cash offer to acquire PolyPeptide Group AG, confirming earlier reports. This definitive move is set to…
Read the complete story, FAQs and key facts.